PlumX Metrics
Embed PlumX Metrics

Bisphosphonate-associated osteonecrosis of the jaw: Report of a Task Force of the American Society for Bone and Mineral Research

Journal of Bone and Mineral Research, ISSN: 0884-0431, Vol: 22, Issue: 10, Page: 1479-1491
2007
  • 1,431
    Citations
  • 0
    Usage
  • 531
    Captures
  • 5
    Mentions
  • 12
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

  • Citations
    1,431
    • Citation Indexes
      1,399
    • Policy Citations
      21
      • Policy Citation
        21
    • Clinical Citations
      11
      • PubMed Guidelines
        11
  • Captures
    531
  • Mentions
    5
    • News Mentions
      4
      • News
        4
    • References
      1
      • Wikipedia
        1
  • Social Media
    12
    • Shares, Likes & Comments
      12
      • Facebook
        12

Most Recent News

Doctors are blasé about bone health, and it’s leading to more broken bones in the elderly

Spread the love Osteoporosis could spiral out of control if we don’t get serious about these screening and treatment issues. At the age of 89,

Review Description

ONJ has been increasingly suspected to be a potential complication of bisphosphonate therapy in recent years. Thus, the ASBMR leadership appointed a multidisciplinary task force to address key questions related to case definition, epidemiology, risk factors, diagnostic imaging, clinical management, and future areas for research related to the disorder. This report summarizes the findings and recommendations of the task force. Introduction: The increasing recognition that use of bisphosphonates may be associated with osteonecrosis of the jaw (ONJ) led the leadership of the American Society for Bone and Mineral Research (ASBMR) to appoint a task force to address a number of key questions related to this disorder. Materials and Methods: A multidisciplinary expert group reviewed all pertinent published data on bisphosphonate-associated ONJ. Food and Drug Administration drug adverse event reports were also reviewed. Results and Conclusions: A case definition was developed so that subsequent studies could report on the same condition. The task force defined ONJ as the presence of exposed bone in the maxillofacial region that did not heal within 8 wk after identification by a health care provider. Based on review of both published and unpublished data, the risk of ONJ associated with oral bisphosphonate therapy for osteoporosis seems to be low, estimated between 1 in 10,000 and <1 in 100,000 patient-treatment years. However, the task force recognized that information on incidence of ONJ is rapidly evolving and that the true incidence may be higher. The risk of ONJ in patients with cancer treated with high doses of intravenous bisphosphonates is clearly higher, in the range of 1-10 per 100 patients (depending on duration of therapy). In the future, improved diagnostic imaging modalities, such as optical coherence tomography or MRI combined with contrast agents and the manipulation of image planes, may identify patients at preclinical or early stages of the disease. Management is largely supportive. A research agenda aimed at filling the considerable gaps in knowledge regarding this disorder was also outlined. © 2007 American Society for Bone and Mineral Research.

Bibliographic Details

Khosla, Sundeep; Burr, David; Cauley, Jane; Dempster, David W; Ebeling, Peter R; Felsenberg, Dieter; Gagel, Robert F; Gilsanz, Vincente; Guise, Theresa; Koka, Sreenivas; McCauley, Laurie K; McGowan, Joan; McKee, Marc D; Mohla, Suresh; Pendrys, David G; Raisz, Lawrence G; Ruggiero, Salvatore L; Shafer, David M; Shum, Lillian; Silverman, Stuart L; Van Poznak, Catherine H; Watts, Nelson; Woo, Sook-Bin; Shane, Elizabeth; American Society for Bone and Mineral Research

Faculty Opinions Ltd

Medicine

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know